Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Non-Current Assets (2020 - 2025)

Tarsus Pharmaceuticals has reported Other Non-Current Assets over the past 6 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $2.0 million for Q4 2025, down 23.0% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (down 23.0% YoY), and the annual figure for FY2025 was $2.0 million, down 23.0%.
  • Other Non-Current Assets for Q4 2025 was $2.0 million at Tarsus Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for TARS hit a ceiling of $2.6 million in Q4 2024 and a floor of $529000.0 in Q1 2023.
  • Median Other Non-Current Assets over the past 5 years was $1.3 million (2021), compared with a mean of $1.4 million.
  • Biggest five-year swings in Other Non-Current Assets: skyrocketed 1290.12% in 2021 and later tumbled 63.9% in 2022.
  • Tarsus Pharmaceuticals' Other Non-Current Assets stood at $1.1 million in 2021, then plummeted by 48.05% to $585000.0 in 2022, then skyrocketed by 158.8% to $1.5 million in 2023, then surged by 71.73% to $2.6 million in 2024, then fell by 23.0% to $2.0 million in 2025.
  • The last three reported values for Other Non-Current Assets were $2.0 million (Q4 2025), $2.6 million (Q3 2025), and $2.6 million (Q2 2025) per Business Quant data.